Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL9P13 is a processed pseudogene derived from the ribosomal protein L9 gene (RPL9), found in the human genome[2]. Unlike the functional RPL9 gene, which encodes a component of the 60S ribosomal subunit and is associated with protein synthesis and certain diseases like Diamond-Blackfan anemia[1], RPL9P13 does not code for a functional protein and does not serve as a target for drugs or have biological activity. Pseudogenes like RPL9P13 are remnants of genes that lost their protein-coding potential due to mutations or genome rearrangements. They are often cataloged in genomic databases, but do not serve as therapeutic targets, biomarkers, or safety concerns for drug development or clinical practice[2]. If you need information about functional ribosomal proteins, such as ribosomal protein L9 (RPL9), these are legitimate molecular targets with established biological roles[1]. However, RPL9P13 is not a therapeutic or biological target; it is a nonfunctional pseudogene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ribosomal protein L9 pseudogene 13 (RPL9P13).